Credit Suisse analyst Brad Canino initiates coverage on Blueprint Medicines (NASDAQ:BPMC) with a Neutral rating and announces Price Target of $100.
Credit Suisse Initiates Coverage On Blueprint Medicines with Neutral Rating, Announces Price Target of $100
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.